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Abstract 
Two facile and efficient one-step procedures for the regioselective synthesis of 7-aryl-5-methyl- and 5-aryl-
7-methyl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidines have been developed, via reactions of 3,5-diamino-1,2,4-
triazole with variously substituted 1-aryl-1,3-butanediones and 1-aryl-2-buten-1-ones, respectively. The 
excellent yield and/or regioselectivity shown by the reactions decreased when ethyl 5-amino-1,2,4-triazole-
3-carboxylate was used. Being the [1,2,4]triazolo[1,5-a]pyrimidine a privileged scaffold, the procedure herein 
reported may be useful for the preparation of biologically active compounds. In this study, the preparation 
of a set of compounds based on the [1,2,4]triazolo[1,5-a]pyrimidine scaffold let to the identification of 
compound 20 endowed with a very promising ability to inhibit influenza virus RNA polymerase PA-PB1 
subunits heterodimerization. 
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Introduction 
[1,2,4]triazolo[1,5-a]pyrimidine is a privileged structure with numerous chemical and biological applications. 
Beside to their great versatility in the interactions with metal ions, [1,2,4]triazolo[1,5-a]pyrimidines showed 
a wide range of biological activities both in agriculture and in medicine.1a,b Examples of biologically active 
compounds include trapidil (Rocornal®, Fig. 1), a platelet-derived growth factor antagonist that has been 
used to treat patients with ischemic coronary heart, liver, and kidney disease,1c and filibuvir (Fig. 1), a non-
nucleoside inhibitor of HCV NS5B polymerase that passed stage II clinical trials, although its clinical 
development program was then suspended.1d Focusing on the most recent literature, compounds based on 
the [1,2,4]triazolo[1,5-a]pyrimidine core have been reported as phosphodiesterase 2 (PDE2a) inhibitors for 
the treatment of memory disorders,2a anti-Alzheimer's disease,2b-d anticancer,2e,f antimalarial,2g,h 
antitubercular,2i antileishmanial,2j antibacterial,2k antiviral,2l hypnotic,2m and CB2 cannabinoid receptor 
inverse agonists.2n 
 
 
Figure 1. Examples of biologically active compounds with a [1,2,4]triazolo[1,5-a]pyrimidine scaffold. 
 
We have also been involved in the synthesis of a series of [1,2,4]triazolo[1,5-a]pyrimidines (compound I and 
structures II and III, Fig. 1)3a,b within our research program on the development of influenza virus (flu) RNA-
dependent RNA polymerase (RdRP) PA-PB1 subunits interaction inhibitors.3 In particular, the synthesis of the 
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anti-flu compounds entailed the preparation of the key intermediate 2-amino-5-methyl-7-phenyl-
[1,2,4]triazolo[1,5-a]pyrimidine (1a) and its isomer 2-amino-7-methyl-5-phenyl-[1,2,4]triazolo[1,5-
a]pyrimidine (2a) (Table 1). 
A major contribution to the chemistry of 2-amino-[1,2,4]triazolo[1,5-a]pyrimidines has been provided by 
Desenko and co-workers, who were the first to report on their synthesis,4 and Chernyshev’s research group, 
who investigated their synthesis further,5a-c their reactivity,5d and their use for the preparation of 
polycondensed heterocycles.5e-h Nevertheless, the synthesis of 7-aryl-5-methyl- and 5-aryl-7-methyl-2-
amino-[1,2,4]triazolo[1,5-a]pyrimidine derivatives has been scarcely explored. In this work, we reported two 
approaches for their preparation via reaction between 3,5-diamino-1,2,4-triazole and variously 
functionalized 1-aryl-1,3-butanediones and 1-aryl-2-buten-1-ones, respectively. Both strategies allowed the 
synthesis of the desired isomer under mild conditions, with high yields, and regioselectively. 
 
Results and discussion 
The synthetic method known for the regioselective preparation of compound 1a, as well as of some 5,7-
diaryl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidines, involves a two-step procedure (Scheme 1) entailing: i) 
cyclocondensation of 3,5-diamino-1,2,4-triazole (3a) with chalcone 4-phenylbut-3-en-2-one (4a) giving2-
amino-5-methyl-7-phenyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine,4a-c and ii) heteroaromatization using 
either N-bromosuccinimide (NBS) or Br2.4a However, the overall yields do not exceed 25-30%. Moreover, NBS 
and Br2 are highly reactive and, thus, this method can only be used to prepare [1,2,4]triazolo[1,5-
a]pyrimidines with limited substitutions at the C-5 and C-7 positions. Increased overall yields up to 40-77% 
were achieved by acetyl protection of the C-2 amino group, by adding Ac2O to the reaction mixture after the 
completion of cyclocondensation, preventing oxidation of the amino group in the successive step.5a Through 
this three-step procedure, compound 1a was regioselectively obtained in 77% yield (Scheme 1).  
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Scheme 1. Known procedures for the synthesis of 1a. 
 
The reaction of 3-amino-1,2,4-triazole bearing different substituents at the C-5 position with unsymmetrically 
1,3-diketones where one of the substituents is a methyl group and the other is a group different from methyl, 
was known from literature to form a mixture of 5-methyl and 7-methyl isomers. The two isomers can be 
distinguished by NMR on the basis of the chemical shifts of the pyrimidine methyl carbon appearing at 24-25 
ppm and 16-17 ppm for the 5-methyl and 7-methyl isomers, respectively.6 Although 5-methyl isomer is 
always the main product of the reaction, the ratio of isomers is influenced: i) by the steric hindrance of the 
substituent on the 1,3-diketone, with a more bulky substituent that gives a higher ratio of 5-methyl isomer, 
and ii) by the inductive effect of the substituent at the C-5 position of the 3-amino-1,2,4-triazole, which 
influences the ratio of isomers much more than the inductive effect of the substituent on the 1,3-diketone 
different from the methyl.6b 
Based on these facts, we hypothesized that, the presumable high nucleophilicity of 3a owing to the presence 
of a second electron-donating amino groups in the molecule,7 might led to an efficient synthesis of 2-amino-
7-aryl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidines by cyclocondensation with 1-aryl-1,3-butanediones. To test 
this idea, we first tried the reaction of 3a with 1-phenyl-1,3-butanedione (5a) in glacial acetic acid at reflux 
(Table 1, entry 1). Actually, Kreutzberger and Risse reported in 1979 that this reaction condition provided a 
mixture of isomers 1a and 2a in 2% and 26% yield, respectively.8 In contrast to what reported by Kreutzberger 
and Risse who mistakenly inverted the assignment of the structures, we were pleased to find that the 
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reaction took place rapidly (4 h), highly efficiently, and, more interestingly, highly regioselectively. Indeed, 2-
amino-5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine (1a) was obtained in 88% yield while its 
regioisomer 2-amino-7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine (2a) was formed only in traces.  
To further explore the reaction conditions, the reaction was then carried out in different solvents. In 
particular, the reaction was repeated in protic and aprotic solvents, i.e. EtOH, DMF, CHCl3, THF, and acetone 
(Table 1), in order to understand whether the acid environment of glacial acetic acid could be essential or 
not for regioselectivity. We also aimed at evaluating the possible influence on tautomerism of 5a, that is well 
known to be extremely sensitive to solvent effect.9 In particular, the enolic form of 5a is much greater in 
nonpolar solvents than in polar or hydrogen-bond donor solvents, since the first ones do not compete with 
hydrogen-bond formation.9a For example, in water compound 5a is extimated to be a mixture of both 
tautomers, with the keto-form being more favoured than the enol one (about 60% and 40%, respectively).9b 
Although data on tautomerism of 5a in glacial acetic acid are not available, it is reasonable to hypothesize 
that in this solvent the keto-form is predominant over the enol one, while, for example, in CHCl3 it is known 
that this compound exists as two kinds of cis-enol forms.9c No significant reaction was observed in CHCl3 
(entry 2), acetone (entry 3), and THF (entry 4) at reflux after 24 h, because of the insolubility of 3a in these 
solvents at the used concentrations. On the other hand, the reaction in EtOH (entry 5) and DMF (entry 6) led 
to the formation of isomer 1a as the main product but in lower yield (57% and 66%, respectively) and much 
more slowly than in acetic acid. Since the reactions did not go to completion under both conditions after 24 
h, we studied the effect of the equiv of 3a (entry 7) as well as the influence of the addition of a base such as 
triethylamine (entries 8) in DMF. Analogously, the reactions were much more slow and less efficient (69% 
and 61%, respectively), but, most importantly, they showed a dramatically decreased regioselectivity. Finally, 
the reaction was carried out in EtOH with the addition of a catalytic amount of acetic acid (entry 9), to verify 
whether a protic solvent in acid conditions could lead to a similar regioselectivity compared to that obtained 
with glacial acetic acid. The presence of acetic acid did not influence the outcome of the reaction, meaning 
that the simple catalytic effect by acid conditions in the condensation reaction is not sufficient to obtain a 
high regioselectivity. 
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Thus, the best reaction conditions are treating 3a (1 equiv) and 5a (1 equiv) in acetic acid at reflux for 4 h. 
Through this one-step procedure, compound 1a was regioselectively obtained in 88% yield. 
 
 
Table 1. Optimization of reaction conditions for 1aa 
 
Entry 
3a  
(equiv) 
Solvent Time (h) 
Yield (%)b 
1a 2a 
1 1 Acetic Acid 4 88 traces 
2 1 CHCl3 24 - - 
3 1 Acetone 24 - - 
4 1 THF 24 - - 
5 1 EtOH 24 57 4 
6 1 DMF 24 66 3 
7 2 DMF 24 39 30 
8 1 
DMF 
(1 equiv of Et3N) 
24 48 13 
9 1 
EtOH 
(0.5 mL of Acetic Acid) 
24 62 5 
 a The reaction was performed on 1.0 mmol scale of 5a in 2.5 mL of solvent at reflux. 
b Determined by 1H NMR.  
 
Utilizing the optimized conditions, we then studied the scope of the reaction (Table 2). Thus, 1-aryl-1,3-
butanediones (5b-k) bearing different electron-donating and electron-withdrawing substituents on the 
phenyl ring were prepared and reacted with 3a. 1-Aryl-1,3-butanediones were in turn synthesized through a 
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Claisen condensation by reacting aryl-methyl ketones with ethyl acetate in the presence of sodium10 (for the 
synthesis and characterization of compounds 5b-k, see SI).  
The results listed in Table 2 show that 1-aryl-1,3-butanediones bearing both electron-donating (entries 2 and 
3) and electron-withdrawing (entry 4) substituents on the phenyl ring are suitable substrates for this reaction, 
reacting smoothly with 3a to give products 1b-d. The effect of the position of electron-withdrawing 
substituents on the phenyl ring was also studied (entries 5 and 6), and the reaction gave consistently good 
yields for compounds 1e and 1f. Multiple electron-donating (entry 7) and electron-withdrawing (entry 8) 
substituents on the 1-aryl-1,3-butanedione phenyl ring gave goods yields. Finally, using 1-(naphthalen-1-
yl)butane-1,3-dione (entry 9) and 1-(pyridin-4-yl)butane-1,3-dione (entry 10), the reaction gave compounds 
1i and 1k in modest yields.      
 
Table 2. Preparation of 2-amino-7-aryl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidinesa 
 
Entry R Time (h) Product Yield (%)b 
1 C6H5 4 1a 88 
2 p-CH3C6H5 3 1b 93 
3 p-CH3SC6H5 4 1c 98 
4 p-BrC6H5 3 1d 98 
5 o-ClC6H5 2 1e 90 
6 m-CF3C6H5 3 1f 86 
7 m,p-Di-CH3OC6H5 3 1g 80 
8 m,p-Di-ClC6H5 2 1h 83 
9 1-Naphthyl 2 1i 62 
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10 4-Pyridinyl 5 1k 65 
 a The reaction was performed on 1.0 mmol scale of 3a and 1 equiv of 5 in 2.5 mL of glacial acetic 
acid at reflux. 
b Isolated yields.                                                                                
 
To further explore the scope of the reaction, 5a was reacted with 5-amino-1,2,4-triazole-3-carboxylic acid, 
characterized by the presence of an electron-withdrawing group at the C-2 position, under the same reaction 
conditions. Unfortunately, the reaction was accompanied by decarboxylation, thus, it was repeated starting 
from ethyl 5-amino-1,2,4-triazole-3-carboxylate (6a). The reaction was equally rapid (4 h) and efficient (80% 
yield) but showed a dramatically decreased regioselectivity, in that ethyl 5-methyl-7-phenyl-
[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxylate (7a) and ethyl 7-methyl-5-phenyl-[1,2,4]triazolo[1,5-
a]pyrimidine-2-carboxylate (8a) were obtained in the ratio of 3.7:1 (Scheme 2). Of note, although not 
regioselective, this reaction permitted to obtain derivatives 7a in acceptable yield (63%) with respect to the 
procedure entailing the reaction of 6a with 4-phenylbut-3-en-2-one (4a) followed by heteroaromatization 
(Scheme 2), which provided compound 7a in a very lower yield (10%).3a  
 
 
Scheme 2. Synthesis of 7a via reaction of 6a with 5a and 4a. *Isolated yields. 
Plausible pathways accounting for the formation of compounds 7a and 8a through the reaction of 6a with 5a 
are speculatively reported in Scheme 3. In particular, an initial direct addition of the amino group at the C(5) 
position of 6a on the carbonyl carbon C(3) of 5a to giǀe a β-aminovinyl ketone, followed by intramolecular 
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cyclization of the latter at the nucleophilic N(1) center of 6a on the carbonyl C(1) of 5a would give 7a (Scheme 
3a). The same pathway may be responsible for the formation of 1a starting from 3a. On the other hand, 
compound 8a could be obtained by: i) an initial direct addition of N(1) of 6a on the carbonyl carbon C(3) of 
5a followed by intramolecular cyclization of the latter by direct addition of the C(5) amino group of 6a on the 
carbonyl C(1) of 5a (Scheme 3b); or ii) an initial direct addition of the C(5) amino group of 6a on the carbonyl 
carbon C(1) of 5a followed by intramolecular cyclization of the latter by direct addition of N(1) of 6a on the 
carbonyl C(3) of 5a (Scheme 3c). 
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Scheme 3. Plausible reaction mechanisms toward 1a, 7a, and 8a. 
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Although a deep investigation of the mechanisms involved in this reaction is beyond the scope of this study, 
the mechanism reported in Scheme 3b was hypothesized as more likely to occur compared to that in Scheme 
3c. Indeed, if the steric hindrance of the phenyl group in 5a was negligible in driving the nucleophilic attack 
of the amino group, the high regioselectivity observed in the reaction of 3a could not be explained. Thus, the 
difference in the regioselectivity shown by the reactions of 3a and 6a with 5a might depend on the different 
nucleophilicity of the two aminotriazoles due to the effect of the substituent. In particular, while the presence 
of a second electron-donating amino group in 3a might be responsible for a higher nucleophilicity of the C(3) 
amino group than N(2), the electron-withdrawing ethyl carboxylate moiety in 6a might led to a smaller 
difference of nucleophilicity between the C(5) amino group and N(1), resulting in a decreased selectivity in 
forming 7a and 8a. Moreover, in the acidic conditions used (pH in glacial acetic acid is reported to be 2.4) 
compound 3a should be almost fully protonated, while about 34% of 6a is in its neutral form according to 
MoKa predictions,11 and this might explain why the nucleophilic attack of N(1) can occur for compound 6a 
(although this remains the minor pathway). Finally, the presence of two amino groups in 3a with a 
presumable comparable nucleophilicity would make their initial attack more probable in 3a than in 6a, as 
also confirmed by lost of regioselectivity observed when one of the two amino groups in 3a was 
dimethylated.6b 
As shown above, the reaction of 3a and 5a under a few different conditions (entries 7 and 8 Table 1) gave a 
mixture of 1a and 2a, of which, however, the latter is always obtained in very low yield (no more than 30% 
yield). Thus, we searched for an alternative synthetic procedure to prepare 2-amino-5-aryl-7-methyl- 
[1,2,4]triazolo[1,5-a]pyrimidine derivatives, taking into account the regioselective cyclocondensation of 3a 
with chalcones.  
The study started by reacting 3a with phenyl-1-propenyl-ketone (9a) in DMF at reflux and by adding Ac2O, in 
order to obtain N-(7-methyl-5-phenyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)acetamide to be then 
heteroaromatized and hydrolysed, to give 2a. After 30 min, the reaction gave a mixture compounds, of which 
one was the already oxidized N-(7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)acetamide 
derivative. Thus, the reaction was repeated without adding Ac2O, in order to directly obtain 2a (Table 3). 
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After 30 min, compound 2a was obtained in 44% yield (entry 1),3a which increased up to 50% yield after 4 h 
(entry 2). 
With these encouraging results, we further explored the reaction conditions. Based on the fact that 
atmospheric O2 can enhance oxidation of 4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidines,13  we hypothesized 
that an higher yield might be achieved by carrying out the reaction in an open flask. Thus, the reaction was 
initially carried out in different solvents (Table 3), i.e. toluene, dioxane, N-methylpyrrolidone (NMP), and DMF 
(CHCl3, acetone, and THF have not been used because of the insolubility of 3a), at 110 °C in an open flask. No 
significant reaction was observed in toluene (entry 3) and dioxane (entry 4) after 24 h, while the reaction in 
NMP (entry 5) provided compound 2a in 25% yield after 4 h. On the other hand, the reaction in DMF (entry 
6) led to the formation of 2a in 57% yield after 2 h. Then, we studied the effect of the equiv of 9a (entry 7), 
the presence of a base such as Et3N (entry 8), and both of them (entry 9) in DMF, and found that the optimum 
reaction conditions are treating 3a (2 equiv) and 9a (1 equiv) in the presence of Et3N (1 equiv) in DMF at 110 
°C for 2 h (entry 9) in an open flask. Through this one-step procedure, compound 2a was regioselectively 
obtained in 80% yield. 
 
 
Table 3. Optimization of reaction conditions for 2a.a 
 
Entry 
3a  
(equiv) 
Et3N 
(equiv) 
Solvent Time (h) Yield (%)b 
1 1 no base DM c 0.5 44 
2 1 no base DMFc 4 50 
3 1 no base Toluene 24 - 
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4 1 no base Dioxane 24 - 
5 1 no base NMP 4 25 
6 1 no base DMF 2 57 
7 2 no base DMF 2 67 
8 1 1 DMF 2 71 
9 2 1 DMF 2 80 
 a Unless otherwise indicated, the reaction was performed on 1.0 mmol scale of 9a in 2.5 mL of solvent 
in an open flask at 110 °C.  
b Isolated yields.                         
c Using the condenser.                                                        
 
 
With these optimized reaction conditions, we next studied the scope of the reaction (Table 4). Thus, 1-aryl-
2-buten-1-ones (9b-i) containing different electron withdrawing as well as electron-donating groups on the 
phenyl ring were synthesized and reacted with 3a. 1-Aryl-2-buten-1-ones were synthesized through a Witting 
reaction. In particular, 2-bromoacetophenones were treated with triphenylphosphine in toluene giving 
triphenylphosphonium bromides,13 which were then reacted with aqueous NaOH in dichloromethane to 
afford 1-aryl-2-(triphenylphosphoranylidene) ethanones, and then with acetaldehyde in a Witting reaction 
to give the corresponding 1-aryl-2-buten-1-ones14 (for the synthesis and characterization of compounds 9b-
i, see SI).  
The results shown in Table 4 highlight that 1-aryl-2-buten-1-ones bearing both electron-donating and 
electron-withdrawing substituents on the phenyl ring are suitable substrates for this reaction. Indeed, with 
the exception of 4-nitrophenyl- (entry 4) and 4-pyridinyl- (entry 9) 2-buten-1-ones, which gave derivatives 2d 
and 2i in modest yields, all the other studied 1-aryl-2-buten-1-ones (entries 2, 3, and 5-7) reacted efficiently 
and regioselectively with 3a to give 2-amino-5-aryl-7-methyl-[1,2,4]triazolo[1,5-a]pyrimidines in consistently 
good yields. 
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Table 4. Preparation of 2-amino-5-aryl-7-methyl-[1,2,4]triazolo[1,5-a]pyrimidines.a  
 
Entry R Time (h) Product Yield (%)b 
1 C6H5 2 2a 80 
2 p-CH3C6H5 3 2b 83 
3 p-CH3OC6H5 2 2c 92 
4 p-NO2C6H5 2 2d 73 
5 p-ClC6H5 2 2e 80 
6 m-BrC6H5 2 2f 87 
7 o-FC6H5 3 2g 80 
8 o,p-Di-FC6H5 2 2h 88 
9 4-Pyridinyl 2 2i 60 
 a The reaction was carried out on 1.0 mmol scale of 3a, 0.5 mmol of 9, and 0.5 mmol of Et3N in 2.5 
mL of DMF in an open flask at 110 °C. 
b Isolated yields.                                                                                
 
To further explore the scope of the reaction, by using the same reaction conditions, 3a was reacted with 4-
phenylbut-3-en-2-one (4a) giving isomer 1a regioselectively in 72% yield after 6 h (Scheme 4a). Of note, 
although in lower yield (72%) than the reaction of 3a with 5a (88% yield), the reaction of 3a with 4a under 
these conditions is an alternative one-step procedure for the regioselective synthesis of 1a, which was 
obtained with comparable yield to that of the known three-step procedure (77% yield).5a Finally, by using the 
same reaction conditions, ethyl 5-amino-1,2,4-triazole-3-carboxylate (6a) was also reacted with both 4a and 
9a. Surprisingly, isomers 7a and 8a were obtained in traces and 19% yield, respectively, after 24 h (Scheme 
4b).  
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Scheme 4 a) Synthesis of 1a via reaction of 3a with 4a; b) Synthesis of 7a and 8a via reaction of 3a with 4a 
and 8a respectively. *Isolated yields. 
 
All the compounds herein reported, with the exception of 1a, were not described previously and their 
structures were fully characterized by spectra data of 1H NMR, 13C NMR, and HRMS. It is worthwhile to 
underline that all the products obtained from both the procedures were purified by simple crystallization 
without the involvement of chromatography. 
 
[1,2,4]triazolo[1,5-a]pyrimidines as anti-flu compounds 
As mentioned above, we have recently identified a series of potent anti-flu compounds based on the 
[1,2,4]triazolo[1,5-a]pyrimidine scaffold that act by inhibiting flu RdRP PA-PB1 subunits interaction.3a In 
particular, within the optimization of compound I (Fig. 1) we prepared a large series of analogues, along with 
a few derivatives characterized by the oxidized [1,2,4]triazolo[1,5-a]pyrimidine scaffold (structure II and III, 
Fig. 1).3a Among them, derivatives 10 and 11 (Table 5) showed a good ability to inhibit flu replication (EC50 = 
42 and 25 μM, respectively) at non toxic concentrations (CC50 > ϮϱϬ μMͿ. Compound 11 also inhibited PA-
PB1 interaction with a comparable IC50 (Ϯϲ μM).  
In order to add structure-activity relationship insights, we decided to exploit the scaffolds herein synthesized 
by preparing an additional set of compounds to study the effect of modifications on the C-5, C-7, and C-2 
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positions of the [1,2,4]triazolo[1,5-a]pyrimidine core. Thus, 2-amino derivatives 1e, 1f, 2c, 2d, and 2e 
variously functionalized at the C-5 or C-7 position were reacted with benzoyl chloride in pyridine at 80 °C 
providing target derivatives 12-16 (Table 5). To study the C-2 position, target compounds 19 and 20 (Table 5) 
were prepared starting from 2-carboxylate scaffolds 7a and 8a, which were hydrolyzed to give intermediates 
17 and 18, chlorinated, and then reacted with 2-aminobenzamide in CH2Cl2 in the presence of DIPEA. 
The synthesized compounds were first evaluated for the ability to inhibit the physical interaction between 
fluA PA and PB1 subunits by ELISA including the Tat-PB11-15 peptide15 as a positive control of inhibition. In 
parallel, for all the synthesized compounds the antiviral activity was tested by plaque reduction assays (PRA) 
in Mardin-Darby canine kidney (MDCK) cells infected with a reference fluA virus, the A/PR/8/34 strain. 
Ribavirin (RBV), a known broad-spectrum inhibitor of RNA viruses polymerase,16 was also included. To 
exclude that the observed antiviral activities could be due to toxic effects on the target cells, the compounds 
were also tested by MTT assays in MDCK cells.  
As shown in Table 5, derivatives 12-16, which were functionalized on the phenyl ring at the C-5 or C-7 
position, although nontoxic, resulted unable to inhibit the viral growth at low micromolar concentrations. 
Nevertheless, p-nitrophenyl and p-chlorophenyl derivatives 15 and 16 showed a good ability to interfere with 
PA-PB1 heterodimerization (IC50 = Ϯϱ aŶd ϰϬ μM, ƌespeĐtiǀelǇͿ. The lack of antiviral activity was shown also 
by compound 19, in which however the presence of the benzamide moiety at the C-2 position led to increase 
of about 15 folds the anti-PA-PB1 activity (IC50 = 11 μMͿ with respect to the strict analogue compound 10 
(IC50 = ϭϲϬ μMͿ. The best and most balanced results was achieved with compound 20, which showed both 
the ability to inhibit viral replication and PA-PB1 heterodimerization at non toxic concentrations. In particular, 
derivative 20 showed a slightly decreased anti-flu activity (EC50 = ϯϭ μMͿ ďut aŶ eŶhaŶĐed aďilitǇ to iŶhiďit 
PA-PB1 complex formation (IC50 = ϭϭ μMͿ ǁith ƌespeĐt to its aŶalogue 11 (IC50 = Ϯϱ μMͿ, and even better than 
the reference PB11–15–Tat peptide (IC50 = 41 μMͿ. 
 
Table 5. Synthesis and biological activity of [1,2,4]triazolo[1,5-a]pyrimidine derivatives. 
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Compd R R’ 
ELISA 
PA-PB1 
Interaction Assay 
IC50, µM
a 
PRA 
in MDCK cells 
EC50, µM
b 
Cytotoxicity 
(MTT Assay) in  
MDCK cells  
CC50, µM
c 
10  C6H5 CH3 160 ± 11 42 ± 5 >250 
11  CH3 C6H5 26 ± 5 25 ± 1 >250 
12  o-ClC6H5 CH3 >200 >100 >250 
13 m-CF3C6H5 CH3 163 ± 20 >100 >250 
14 CH3 p-CH3OC6H5 160 ± 1 92 ± 5 >250 
15 CH3 p-NO2C6H5 25 ± 2 92 ± 5 >250 
16 CH3 p-ClC6H5 40 ± 4 99 ± 2 >250 
 
 
 
Compd R R’ 
ELISA 
PA-PB1 
Interaction Assay 
IC50, µM
a 
PRA 
in MDCK cells 
EC50, µM
b 
Cytotoxicity 
(MTT Assay) in  
MDCK cells CC50, 
µMc 
19 C6H5 CH3 11 ± 3 >100 >250 
20 CH3 C6H5 7 ± 1 31 ± 10 >250 
 
Tat-PB11-15 
peptide 
  35 ± 4 41 ± 5 >100 
RBV    10 ± 2 >250 
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a Compounds activity in ELISA PA−PB1 interaction assays. The IC50 value is defined as the compound 
concentration that reduces the PA-PB1 interaction by 50%. b Antiviral activity of the compounds against 
the fluA A/PR/8/34 strain in plaque reduction assays. The EC50 value represents the effective compound 
concentration required to reduce virus plaque formation by 50%. c Citotoxicity of the compounds in MTT 
assays. The CC50 value represents the compound concentration resulting in 50% inhibition of MDCK cell 
viability. All the reported values represent the means ± SD of data obtained from at least three 
independent experiments in duplicate. 
 
 
Conclusions 
In summary, two facile and efficient one-step procedures for the regioselective synthesis of 7-aryl-5-methyl- 
and 5-aryl-7-methyl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidines have been developed. These procedures have 
proven to be suitable for 1-aryl-1,3-butanediones and 1-aryl-2-buten-1-ones with different substitution 
patterns on the phenyl ring, permitting to obtain 2-amino-[1,2,4]triazolo[1,5-a]pyrimidines variously 
functionalized at the C-5 and C-7 positions, respectively. The synthesized derivatives may be useful for the 
preparation of biologically active compounds. In this study, they have been used for the synthesis of a set of 
[1,2,4]triazolo[1,5-a]pyrimidine derivatives as anti-flu compounds. From this study, derivative 20 emerged as 
a new potential antiviral compound endowed with a very good ability to inhibit flu RNA polymerase complex 
formation. 
 
Experimental  
Material and methods 
Commercially available starting materials, reagents, and solvents were used as supplied. Compounds 4-
phenylbut-3-en-2-one (4a), 1-phenyl-1,3-butanedione (5a), and phenyl-1-propenyl-ketone (9a) were 
purchased from Alfa Aesar and Apollo Scientific. Synthesis of 1-aryl-1,3-butanediones (5b-k) and 1-aryl-2-
buten-1-ones (9b-i) was reported in the SI. Compound 5-amino-1,2,4-triazole-3-carboxylate (6a) was 
synthesized as reported in literature.17 Hydrolysis of compounds 8a and 9a to [1,2,4]triazolo[1,5-
a]pyrimidine-2-carboxylic acid 16 and 17, respectively, was carried out as previously reported by us.3a 
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All reactions were routinely monitored by TLC on silica gel 60F254 (Merck) and visualized by using UV or 
iodine. Flash column chromatography was performed on Merck silica gel 60 (mesh 230-400). After extraction, 
organic solutions were dried over anhydrous Na2SO4, filtered, and concentrated with a Büchi rotary 
evaporator at reduced pressure. Yields are of purified product and were not optimized. HRMS spectra were 
registered on Agilent Technologies 6540 UHD Accurate Mass Q-TOF LC/MS, HPLC 1290 Infinity. Purities of 
compounds 12-16, 19, and 20 were determined by UHPLC on Agilent Technologies 6540 UHD Accurate Mass 
Q-TOF LC/MS, HPLC 1290 Infinity with DAD detector and evaluated to be 100% pure. HPLC conditions to 
assess the purity of final compounds were as follows: column, Phenomenex AERIS Widepore C4, 4.6mm  × 
ϭϬϬ ŵŵ ;ϲ.ϲ μŵͿ; floǁ ƌate, Ϭ.ϴϱ ŵL/ŵiŶ; aĐƋuisitioŶ tiŵe, ϭϬ ŵiŶ; DAD 254 nm; oven temperature, 30 °C; 
gƌadieŶt of aĐetoŶitƌile iŶ ǁateƌ ĐoŶtaiŶiŶg Ϭ.ϭ% of foƌŵiĐ aĐid ;Ϭ−ϭϬϬ% iŶ ϭϬ ŵiŶͿ. 1H NMR and 13C NMR 
spectra were recorded on Bruker Avance DRX-ϰϬϬMHz usiŶg ƌesidual solǀeŶts suĐh as diŵethǇlsulfoǆide ;δ = 
2.48) or Đhloƌofoƌŵ ;δ = ϳ.ϮϲͿ as aŶ iŶteƌŶal staŶdaƌd. CheŵiĐal shifts ǁeƌe ƌeĐoƌded iŶ ppŵ ;δͿ aŶd the 
spectral data are consistent with the assigned structures. The spin multiplicities are indicated by the: symbols 
s (singolet), d (doublet), t (triplet), q (quartet), m (multiplet), and bs (broad singolet).  
General procedure for the synthesis of 2-amino-7-aryl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidines (1a-k). A 
mixture of the appropriate 1-aryl-1,3-butanedione (5a-k) (1 mmol) and 3a (1 mmol) in glacial acetic acid (2.5 
mL) was refluxed until no starting material was detected by TLC (2-5h). After cooling, the reaction mixture 
was poured into ice/water and neutralized with 10% NaOH, obtaining a precipitate that was filtered and 
crystallized by EtOH/DMF.  
5-Methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (1a). White crystals. 1H NMR (400 MHz, DMSO-
d6) : 2.52 (s, 3H, CH3), 6.32 (s, 2H, NH2), 7.14 (s, 1H, H-6), 7.56-7.57 (m, 3H, aromatic CH), 8.10-8.12 (m, 2H, 
aromatic CH); 13C NMR (101 MHz, DMSO-d6) : 24.1, 107.3, 128.4, 129.1, 130.3, 131.0, 143.8, 155.7, 161.6, 
167.1; HRMS: m/z calcd for C12H11N5 226.1093 (M + H+), found 226.1021 (M + H+). 
5-Methyl-7-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (1b). White crystals. 1H NMR (400 MHz, DMSO-
d6) : 2.38 and 2.51 (s, each 3H, CH3), 6.32 (s, 2H, NH2), 7.15 (s, 1H, H-6), 7.37 and 8.06 (d, J = 8.0 Hz, each 2H, 
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aromatic CH); 13C NMR (101 MHz, DMSO-d6) : 21.1, 24.1, 106.9, 127.4, 129.0, 129.1, 141.2, 143.8, 155.8, 
161.5, 167.1; HRMS: m/z calcd for C13H13N5 240.1250 (M + H+), found 240.1249 (M + H+).  
5-Methyl-7-(4-(methylthio)phenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (1c). Light yellow crystals. 1H 
NMR (400 MHz, DMSO-d6) : 2.51 and 2.54 (s, each 3H, CH3), 6.32 (s, 2H, NH2), 7.17 (s, 1H, H-6), 7.41 and 
8.13 (d, J = 8.5 Hz, each 2H, aromatic CH); 13C NMR (101 MHz, DMSO-d6) : 14.1, 24.1, 106.7, 124.9, 126.1, 
129.5, 142.7, 143.3, 155.8, 161.5, 167.0; HRMS: m/z calcd for C13H13N5S 272.0971 (M + H+), found 272.0968 
(M + H+). 
7-(4-Bromophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (1d). Light yellow crystals. 1H NMR 
(400 MHz, DMSO-d6) : 2.52 (s, 3H, CH3), 6.35 (s, 2H, NH2), 7.19 (s, 1H, H-6), 7.78 and 8.09 (d, J = 8.5 Hz, each 
2H, aromatic CH); 13C NMR (101 MHz, DMSO-d6) : 24.1, 107.3, 124.7, 129.5, 131.2, 131.5, 142.6, 155.7, 
161.6, 167.1; HRMS: m/z calcd for C12H10BrN5 304.0199 (M + H+), found 304.0199 (M + H+). 
7-(2-Chlorophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (1e). Light yellow powder. 1H NMR 
(400 MHz, DMSO-d6) : 2.53 (s, 3H, CH3), 6.31 (s, 2H, NH2), 6.99 (s, 1H, H-6), 7.51-7.65 (m, 4H, aromatic CH); 
13C NMR (101 MHz, DMSO-d6) : 24.1, 109.0, 127.4, 129.5, 130.3, 131.4, 131.9, 132.1, 142.2, 154.9, 161.5, 
167.2; HRMS: m/z calcd for C12H10ClN5 260.0704 (M + H+), found 260.0702 (M + H+). 
5-Methyl-7-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (1f). Light yellow crystals. 
1H NMR (400 MHz, DMSO-d6) : 2.54 (s, 3H, CH3), 6.38 (bs, 2H, NH2), 7.29 (s, 1H, H-6), 7.82 (t, J = 7.8 Hz, 1H, 
aromatic CH), 7.95 and 8.40 (d, J = 7.8 Hz, each 1H, aromatic CH), 8.48 (s, 1H, aromatic CH); 13C NMR (101 
MHz, DMSO-d6) : 24.1, 107.9, 125.8 (q, JC-F = 3.03 Hz), 126.6 (q, JC-F = 2.72.7 Hz), 127.5 (q, JC-F = 3.03 Hz), 
129.2 (d, JC-F = 32.3 Hz), 129.7, 131.4, 133.2, 142.2, 155.6, 161.8, 167.0; HRMS: m/z calcd for C13H10F3N5 
294.0961 (M + H+), found 294.0967 (M + H+). 
7-(3,4-Dimethoxyphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (1g). Light yellow crystals. 1H 
NMR (400 MHz, DMSO-d6) : 2.50 (s, 3H, CH3), 3.84 (s, 6H, OCH3), 6.28 (s, 2H, NH2), 7.11 (d, J = 8.5 Hz, 1H, 
aromatic CH), 7.20 (s, 1H, H-6), 7.77 (d, J = 1.8 Hz, 1H, aromatic CH), 7.90 (dd, J = 1.8 and 8.5 Hz, 1H, aromatic 
CH); 13C NMR (101 MHz, DMSO-d6) : 24.1, 55.7, 55.7, 106.5, 111.2, 112.6, 122.3, 122.9, 143.6, 148.3, 151.1, 
155.9, 161.3, 166.9; HRMS: m/z calcd for C14H15N5O2 286.1305 (M + H+), found 286.1303 (M + H+). 
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7-(3,4-Dichlorophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (1h). Light yellow crystals. 1H 
NMR (400 MHz, DMSO-d6) : 2.52 (s, 3H, CH3), 6.41 (s, 2H, NH2), 7.27 (s, 1H, H-6), 7.85 (d, J = 8.5 Hz, 1H, 
aromatic CH), 8.12 (dd, J = 2.0 and 8.5 Hz, 1H, aromatic CH) 8.47 (d, J = 2.0 Hz, 1H, aromatic CH); 13C NMR 
(101 MHz, DMSO-d6) : 24.1, 107.6, 129.3, 130.7, 131.7, 131.0, 131.3, 133.7, 141.1, 155.7, 161.7, 167.1; 
HRMS: m/z calcd for C12H9Cl2N5 294.0314 (M + H+), found 294.0315 (M + H+). 
5-Methyl-7-(naphthalen-1-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (1i). White powder. 1H NMR (400 
MHz, DMSO-d6) : 2.56 (s, 3H, CH3), 6.17 (s, 2H, NH2), 7.03 (s, 1H, H-6), 7.36 (d, J = 8.3 Hz, 1H, naphthalene 
CH), 7.45-7.49 and 7.54-7.58 (m, each 1H, naphthalene CH), 7.62-7.69 (m, 2H, naphthalene CH), 8.03 and 
8.12 (d, J = 8.0 Hz, each 1H, naphthalene CH); 13C NMR (101 MHz, DMSO-d6) : 24.3, 110.0, 125.2, 125.5, 
126.6, 127.3, 127.9, 128.5, 129.0, 129.8, 130.6, 133.0, 144.2, 155.1, 161.9, 167.1; HRMS: m/z calcd for 
C16H13N5 276.125 (M + H+), found 276.1247 (M + H+). 
5-Methyl-7-(pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (1k). White crystals. 1H NMR (400 MHz, 
DMSO-d6) : 2.54 (s, 3H, CH3), 6.42 (s, 2H, NH2), 7.30 (s, 1H, H-6), 8.10 and 8.80 (d, J = 4.6 Hz, each 2H, pyridine 
CH); 13C NMR (101 MHz, DMSO-d6) : 24.2, 107.7, 123.0, 137.7, 141.1, 150.1, 155.6, 161.8, 167.2; HRMS: m/z 
calcd for C11H10N6 227.1046 (M + H+), found 227.1044 (M + H+). 
Ethyl 5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxylate (7a) and ethyl 7-methyl-5-phenyl-
[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxylate (8a). The title compounds were prepared through the 
general procedure for the synthesis of 2-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidines by replacing 3a 
with ethyl 5-amino-1,2,4-triazole-3-carboxylate (6a),15 and were separated by flash chromatography eluting 
with CHCl3/acetone (9:1). 7a: white solid (63% yield); 1H NMR (400 MHz, DMSO-d6) : 1.31 (t, J = 7.0 Hz, 
CH2CH3), 2.69 (s, 3H, CH3), 4.38 (q, J = 7.0 Hz, CH2CH3), 7.63-7.65 (m, 4H, H-6 and aromatic CH), 8.07-8.09 (m, 
2H, aromatic CH); 13C NMR (101 MHz, DMSO-d6) : 14.1, 24.8, 61.7, 112.2, 128.7, 129.3, 129.5, 131.7, 146.7, 
155.6, 155.9, 160.0, 166.9; HRMS: m/z calcd for C15H14N4O2 283.1196 (M + H+), found 283.1196 (M + H+); 8a: 
white solid (17% yield); 1H NMR (400 MHz, DMSO-d6) : 1.35 (t, J = 7.0 Hz, CH2CH3), 2.84 (s, 3H, CH3), 4.41 (q, 
J = 7.0 Hz, CH2CH3), 7.59-7.60 (m, 3H, aromatic CH), 8.10 (s, 1H, H-6), 8.25-8.27 (m, 2H, aromatic CH); 13C NMR 
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(101 MHz, DMSO-d6) : 14.1, 17.0, 61.7, 108.9, 127.7, 129.2, 131.7, 135.7, 149.1, 155.0, 156.3, 159.9, 161.3; 
HRMS: m/z calcd for C15H14N4O2 283.1196 (M + H+), found 283.1194 (M + H+). 
General procedure for the synthesis of 2-amino-5-aryl-7-methyl-[1,2,4]triazolo[1,5-a]pyrimidines (2a-i). To 
a mixture of the appropriate 1-aryl-2-buten-1-ones (9a-i) (0.5 mmol) and 3a (1 mmol) in dry DMF (2.5 mL), 
dry Et3N (0.5 mmol) was added and the reaction mixture was heated at 110 °C until no starting material was 
detected by TLC (2-3h). After cooling, the reaction mixture was poured into ice/water, obtaining a precipitate 
that was filtered and crystallized by EtOH/DMF. 
7-Methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (2a). Light yellow crystals. 1H NMR (400 MHz, 
DMSO-d6) : 2.64 (s, 3H, CH3), 6.41 (s, 2H, NH2), 7.49-7.54 (m, 3H, aromatic CH), 7.59 (s, 1H, H-6), 8.13-8.15 
(m, 2H, aromatic CH); 13C NMR (101 MHz, DMSO-d6) : 17.1, 104.7, 127.0, 128.9, 130.4, 136.7, 145.4, 155.1, 
156.8, 167.5; HRMS: m/z calcd for C12H11N5 226.1093 (M + H+), found 266.1088 (M + H+). 
7-Methyl-5-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (2b). Light yellow crystals. 1H NMR (400 MHz, 
DMSO-d6) : 2.36 and 2.63 (s, each 3H, CH3), 6.38 (s, 2H, NH2), 7.32 (d, J = 6.0 Hz, each 1H, aromatic CH), 7.55 
(s, 1H, H-6), 8.05 (d, J = 6.0 Hz, each 1H, aromatic CH); 13C NMR (101 MHz, DMSO-d6) : 17.4, 21.3, 104.7, 
127.2, 129.8, 134.2, 140.6, 145.7, 155.4, 157.2, 167.7; HRMS: m/z calcd for C13H13N5 240.1250 (M + H+), found 
240.1251 (M + H+). 
5-(4-Methoxyphenyl)-7-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (2c). Yellow crystals. 1H NMR (400 
MHz, DMSO-d6) : 2.62 (s, 3H, CH3), 3.82 (s, 3H, OCH3), 6.34 (s, 2H, NH2), 7.06 (d, J = 8.8 Hz, 2H, aromatic CH), 
7.51 (s, 1H, H-6), 8.11 (d, J = 8.8 Hz, 2H, aromatic CH); 13C NMR (101 MHz, DMSO-d6) : 17.0, 55.4, 104.0, 
114.0, 128.6, 129.0, 145.2, 155.1, 156.7, 161.2, 167.3; HRMS: m/z calcd for C13H13N5O 256.1199 (M + H+), 
found 256.1193 (M + H+). 
7-Methyl-5-(4-nitrophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (2d). Yellow crystals. 1H NMR (400 MHz, 
DMSO-d6) : 2.66 (s, 3H, CH3), 6.54 (s, 2H, NH2), 7.71 (s, 1H, H-6), 8.33 and 8.38 (d, J = 8.9 Hz, each 2H, aromatic 
CH); 13C NMR (101 MHz, DMSO-d6) : 17.3, 105.7, 124.2, 128.3, 142.7, 146.0, 148.4, 154.2, 155.1, 167.9; m/z 
calcd for C12H10N6O2 271.0944 (M + H+), found 271.0944 (M + H+). 
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5-(4-Chlorophenyl)-7-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (2e). Yellow crystals. 1H NMR (400 
MHz, DMSO-d6) : 2.64 (s, 3H, CH3), 6.45 (s, 2H, NH2), 7.57-7.61 (m, 3H, aromatic CH and H-6), 8.17 (d, J = 8.4 
Hz, 2H, aromatic CH); 13C NMR (101 MHz, DMSO-d6) : 17.1, 104.6, 128.8, 129.0, 135.2, 135.5, 145.6, 155.0, 
155.4, 167.6; HRMS: m/z calcd for C12H10ClN5 260.0704 (M + H+), found 260.0681 (M + H+). 
5-(3-Bromophenyl)-7-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (2f). Light brown crystals. 1H NMR 
(400 MHz, DMSO-d6) : 2.63 (s, 3H, CH3), 6.42 (s, 2H, NH2), 7.47 (t, J = 7.8 Hz, 1H, aromatic CH), 7.61 (s, 1H, 
H-6), 7.67 and 8.12 (d, J = 7.8 Hz, each 1H, aromatic CH), 8.29 (s, 1H, aromatic CH); 13C NMR (101 MHz, DMSO-
d6) : 17.3, 105.2, 122.6, 126.2, 129.7, 131.4, 133.3, 139.1, 146.1, 155.2, 155.4, 167.7; HRMS: m/z calcd for 
C12H10BrN5 304.0199 (M + H+), found 304.0194 (M + H+). 
5-(2-Fluorophenyl)-7-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (2g). Yellow crystals. 1H NMR (400 
MHz, DMSO-d6) : 2.66 (s, 3H, CH3), 6.49 (s, 2H, NH2), 7.33-7.51 (m, 3H, aromatic CH and H-6), 7.52-7.57 (m, 
1H, aromatic CH), 7.97 (dt, J = 1.5 and 7.8 Hz, 1H, aromatic CH); 13C NMR (101 MHz, DMSO-d6) : 17.1, 108.2 
(d, J = 10.1 Hz), 116.5 (d, J = 22.2 Hz), 125.0, 125.1 (d, J = 22.2 Hz), 130.9 (d, J = 3.0 Hz), 132.1 (d, J = 8.0 Hz), 
145.2, 153.4, 154.9, 160.0 (d, J = 251.4 Hz), 167.6; HRMS: m/z calcd for C12H10FN5 244.0999 (M + H+), found 
244.0997 (M + H+). 
5-(2,4-Difluorophenyl)-7-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (2h). Light yellow crystals. 1H NMR 
(400 MHz, DMSO-d6) : 2.65 (s, 3H, CH3), 6.49 (s, 2H, NH2), 7.24-7.29 (m, 2H, aromatic CH), 7.31 (s, 1H, H-6), 
7.41-7.47 and 8.02-8.08 (m, each 1H, aromatic CH); 13C NMR (101 MHz, DMSO-d6) : 17.1, 104.9 (t, JC-F = 26.7 
Hz), 107.9 (d, JC-F = 10.1 Hz), 112.4 (dd, JC-F = 3.0 and 21.2 Hz), 122.0 (dd, JC-F = 4.0 and 13.1 Hz), 132.4 (dd, JC-F 
= 4.0 and 11.1 Hz), 145.3, 152.5, 154.9, 160.3 (dd, JC-F = 13.1 and 251.4 Hz), 163.2 (dd, JC-F = 13.1 and 252.5 
Hz), 167.3; HRMS: m/z calcd for C12H9F2N5 262.0905 (M + H+), found 262.0899 (M + H+). 
7-Methyl-5-(pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (2i). Yellow crystals. 1H NMR (400 MHz, 
DMSO-d6) : 2.68 (s, 3H, CH3), 6.56 (s, 2H, NH2), 7.73 (s, 1H, H-6), 8.07 and 8.73 (dd, J = 1.6 and 4.6 Hz, each 
2H, pyridine CH); 13C NMR (101 MHz, DMSO-d6) : 17.2, 105.2, 120.9, 143.7, 145.9, 150.5, 154.0, 155.0, 167.8; 
HRMS: m/z calcd for C11H10N6 227.1046 (M + H+), found 277.1041 (M + H+). 
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General procedure for the synthesis of compounds 12-16 by amidation. A solution of benzoyl chloride (2.0 
mmol) in dry pyridine (5 mL) was added dropwise to a solution of the appropriate [1,2,4]triazolo[1,5-
a]pyrimidine-2-amine (1e, 1f, 2c, 2d, or 2e)  (1.0 mmol) in dry pyridine (15 mL), and then the reaction mixture 
was maintained at 80 °C overnight. After cooling, it was poured into ice/water, obtaining a precipitate that 
was filtered and purified as described below. 
N-(7-(2-chlorophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (12). The title compound 
was prepared starting from 1e and purified by flash chromatography eluting with CH2Cl2/MeOH (98:2) in 71% 
yield as white solid. 1H NMR (400 MHz, DMSO-d6) : 2.67 (s, 3H, CH3), 7.34 (s, 1H, H-6), 7.46-7.50 and 7.57-
7.58 (m, each 2H, aromatic CH), 7.64 (t, J = 7.2 Hz, 1H, aromatic CH), 7.70-7.72 (m, 2H, aromatic CH), 7.96 (d, 
J = 7.5 Hz, 2H, aromatic CH), 11.30 (s, 1H, NH); 13C NMR (101 MHz, DMSO-d6) : 24.6, 112.0, 127.5, 128.0, 
128.3, 129.6, 129.7, 131.5, 132.1, 132.3, 132.3, 133.4, 143.9, 154.0, 160.1, 164.6, 164.8.; HRMS: m/z calcd 
for C19H14ClN5O 364.0966 (M + H+), found 364.0965 (M + H+).  
N-(5-methyl-7-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (13). The title 
compound was prepared starting from 1f and purified by flash chromatography eluting with CH2Cl2/MeOH 
(98:2) in 45% yield as white solid. 1H NMR (400 MHz, DMSO-d6) : 2.67 (s, 3H, CH3), 7.48-7.52 (m, 2H, aromatic 
CH), 7.57-7.61 (m, 1H, aromatic CH), 7.63 (s, 1H, H-6), 7.87 (t, J = 7.8 Hz, 1H, aromatic CH), 7.99-8.01 (m, 3H, 
aromatic CH), 8.51 (d, J = 7.9 Hz, 1H, aromatic CH), 8.59 (s, 1H, aromatic CH), 11.34 (s, 1H, NH); 13C NMR (101 
MHz, DMSO-d6) : 24.5, 110.3, 123.8 (q, J = 273.7 Hz), 126.2 (q, J = 3.0 Hz), 127.9 (q, J = 3.0 Hz), 128.0, 128.3, 
129.4 (q, J = 32.3 Hz), 129.8, 130.7, 132.1, 133.4, 133.5, 154.6, 159.9, 164.6, 164.8; HRMS: m/z calcd for 
C20H14F3N5O 398.1229 (M + H+), found 398.1227 (M + H+).  
N-(5-(4-methoxyphenyl)-7-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (14). The title compound 
was prepared starting from 2c and purified by flash chromatography eluting with CH2Cl2/acetone (8:2) in 62% 
yield as white solid. 1H NMR (400 MHz, DMSO-d6) : 2.78 and 3.84 (s, each 3H, CH3), 7.11 (d, J = 8.8 Hz, 2H), 
7.50-7.54 (m, 2H, aromatic CH), 7.60 (d, J = 7.2 Hz, 1H, aromatic CH), 7.84 (s, 1H, H-6), 8.02 (d, J = 7.4 Hz, 2H, 
aromatic CH), 8.22 (d, J = 8.8 Hz, 2H, aromatic CH), 11.34 (s, 1H, NH);  13C NMR (101 MHz, DMSO-d6) : 17.4, 
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55.8, 106.6, 114.8, 128.4, 128.8, 128.8, 129.4, 132.5, 134.0, 147.7, 154.5, 159.4, 160.5, 162.1, 165.2; HRMS: 
m/z calcd for C20H17N5O2 360.1461 (M + H+), found 360.1460 (M + H+).  
N-(7-methyl-5-(4-nitrophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (15). The title compound 
was prepared starting from 2d and purified by flash chromatography eluting with CH2Cl2/acetone (8:2) in 64% 
yield as white solid. 1H NMR (400 MHz, DMSO-d6) : 2.82 (s, 3H, CH3), 7.50-7.54 (m, 2H, aromatic CH),  7.60 
(t, J = 7.2 Hz, 1H, aromatic CH), 8.01-8.03 (m, 3H, H-6 and aromatic CH), 8.39 and 8.46 (d, J = 8.8 Hz, each 2H 
aromatic CH), 11.47 (s, 1H, NH); 13C NMR (101 MHz, DMSO-d6) : 17.2, 107.6, 124.1, 128.1, 128.4, 128.6, 
132.2, 133.6, 142.0, 148.4, 148.7, 153.9, 156.7, 160.9, 164.8; HRMS: m/z calcd for C19H14N6O3 375.1206 (M + 
H+), found 375.1201 (M + H+). 
N-(5-(4-chlorophenyl)-7-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (16). The title compound 
was prepared starting from 2e and purified by flash chromatography eluting with CH2Cl2/acetone (8:2) in 52% 
yield as white solid. 1H NMR (400 MHz, DMSO-d6) : 2.78 (s, 3H, CH3), 7.48-7.52 (m, 2H, aromatic CH), 7.57-
7.63 (m, 3H, aromatic CH), 7.90 (s, 1H, H-6), 8.00 and 8.23 (d, J = 8.2 Hz, each 2H, aromatic CH), 11.38 (s, 1H, 
NH); 13C NMR (101 MHz, DMSO-d6) : 17.1, 106.8, 128.1, 128.4, 129.1, 129.1, 132.1, 133.6, 135.0, 136.0, 
147.9, 153.9, 158.0, 160.5, 164.8; HRMS: m/z calcd for C19H13F2N5O 366.1167 (M + H+), found C19H14ClN5O 
364.0966 (M + H+), found 364.0963 (M + H+). 
General procedure for the synthesis of compounds 19 and 20 by amidation. To a solution of the appropriate 
[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxylic acid (173a or 183a) (2 mmol) in well dry CH2Cl2 (20 mL), oxalyl 
chloride (12 mmol) was added and after 30 min dry DMF (2 drops) was added. After 2 h, the reaction mixture 
was evaporated to dryness to give a residue that was dissolved in well dry CH2Cl2 and added of the 
appropriate aniline (2 mmol) and DIPEA (2 mmol). The reaction was maintained at rt until no starting material 
was detected by TLC (4h for 19 and 1h for 20). The work up of the reaction and compound purification are 
reported below.   
N-(2-carbamoylphenyl)-5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (19). The 
reaction mixture was evaporated to dryness and treated with ice/water obtaining a precipitate that was 
filtered and purified by flash chromatography eluting with CH2Cl2/MeOH (98:2), to give 19 in 52% yield; 1H-
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NMR (DMSO-d6) :  2.70 (s, 3H, CH3), 7.20 and 7.57 (t, J = 7.5 Hz, each 1H, aromatic CH), 7.69-7.62 (m, 4H, H-
6 and aromatic CH), 7.75 (bs, 1H, CONH2), 7.84 (d, J = 7.7 Hz, 1H, aromatic CH), 8.25-8.19 (m, 2H, aromatic 
CH), 8.33 (bs, 1H, CONH2), 8.66 (d, J = 8.2 Hz, 1H, aromatic CH), 13.14 (s, 1H, NH); 13C NMR (101 MHz, DMSO-
d6) : 25.0, 111.9, 120.5, 120.8, 123.6, 128.9, 129.0, 129.4, 129.8, 132.0, 132.6, 138.7, 146.8, 155.8, 157.4, 
158.6, 167.0, 170.6; HRMS: m/z calcd for C20H16N6O2 373.1414 (M + H+), found 373.1411 (M + H+). 
N-(2-carbamoylphenyl)-7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (20). The 
reaction mixture was filtered and the precipitate was washed with Et2O, and then purified by flash 
chromatography eluting with CH2Cl2/MeOH (98:2), to give 20 in 59% yield as white solid. 1H NMR (400 MHz, 
DMSO-d6) : 2.88 (s, 3H, CH3), 7.22 (t, J = 7.5 Hz, 1H, aromatic CH), 7.57-7.60 (m, 4H, aromatic CH), 7.78 (bs, 
1H, CONH2), 7.86 (d, J = 7.8 Hz, 1H, aromatic CH), 8.10 (s, 1H, H-6), 8.38 – 8.25 (m, 3H, aromatic CH and 
CONH2), 8.73 (d, J = 8.3 Hz, 1H, aromatic CH, 13.16 (s, 1H, NH); 13C NMR (101 MHz, DMSO-d6) : 17.0, 108.7, 
120.4, 120.6, 123.3, 127.7, 128.7, 129.2, 131.6, 132.3, 135.8, 138.6, 149.1, 154.9, 157.2, 158.9, 161.2, 170.4; 
HRMS: m/z calcd for C20H16N6O2 373.1414 (M + H+), found 373.1413 (M + H+). 
Biological assays 
Compounds and peptide. RBV (1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) was purchased from Roche. 
Each test compound was dissolved in 100% DMSO. The PB11–15–Tat peptide was synthesized and purified by 
the Peptide Facility of CRIBI Biotechnology Center (University of Padua, Padua, Italy). This peptide 
corresponds to the first 15 amino acids of PB1 protein fused to a short sequence of HIV Tat protein (amino 
aĐids ϰϳ−ϱϵͿ, ǁhiĐh alloǁs the deliǀeƌǇ iŶto the Đell.18 
Cells and virus. Mardin-DaƌďǇ ĐaŶiŶe kidŶeǇ ;MDCKͿ Đells ǁeƌe gƌoǁŶ iŶ DulďeĐĐo’s ŵodified Eagle’s ŵediuŵ 
(DMEM, Life Biotechnologies) supplemented with 10% (v/v) fetal bovine serum (FBS, Life Technologies) and 
antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin, Life Technologies). The cells were maintained 
at 37 °C in a humidified atmosphere with 5% CO2. Influenza virus strain A/PR/8/34 (H1N1, Cambridge lineage) 
was kindly provided by P. Digard (Roslin Institute, University of Edinburgh, United Kingdom).  
PA-PB1 interaction enzyme-linked immunosorbent assay (ELISA). The PA−PBϭ iŶteƌaĐtioŶ ǁas deteĐted as 
described,3c with some modifications.19 Briefly, 96-well microtiter plates (Nuova Aptca) were coated with 400 
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ng of 6His--PA(239−716) for 3 h at 37 °C and then blocked with 2% BSA (Sigma) in PBS for 1 h at 37 °C. The 6His-
-PA(239−716) protein was expressed in E. coli strain BL21(DE3)pLysS and purified as already described.3cAfter 
washing, 200 ng of GST-PB1(1−25), or of GST alone as a control, in the absence or the presence of test 
compounds at various concentrations, were incubated in serum-free DMEM O/N at room temperature as 
described.19 Escherichia coli-expressed, purified GST and GST-PB1(1−25) proteins were obtained as previously 
described.3c,20 After washing, the interaction between 6His--PA(239−716) and GST-PB1(1−25) was detected with a 
horseradish peroxidase-coupled anti-GST monoclonal antibody (GenScript) diluted 1:4,000 in PBS 
supplemented with 2% FBS. Following washes, the substƌate ϯ,ϯ′,ϱ,ϱ′tetƌaŵethǇlďeŶzidiŶe ;TMB, KPLͿ ǁas 
added aŶd aďsoƌďaŶĐe ǁas ŵeasuƌed at ϰϱϬ Ŷŵ ďǇ aŶ ELISA plate ƌeadeƌ ;TeĐaŶ SuŶƌise™Ϳ. Values oďtaiŶed 
fƌoŵ the saŵples tƌeated ǁith oŶlǇ DMSO ǁeƌe used to set as ϭϬϬ% of PA−PBϭ iŶteƌaĐtioŶ.  
Cytotoxicity assay. Cytotoxicity of compounds was tested in MDCK cells by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) method, as previously reported.3c,21 Briefly, MDCK cells (seeded at 
density of 2 x 104  per well) were grown in 96-well plates for 24 h and then treated with serial dilutions of 
test compounds, or DMSO as a control, in DMEM supplemented with 10% FBS. After incubation at 37 °C for 
48 h, 5 mg/mL of MTT (Sigma) in PBS was added into each well and incubated at 37 °C for further 4 h. 
Successively, a solubilization solution was added to lyse the cells and incubated O/N at 37 °C. Finally, optical 
density was read at the wavelength of 620 nm on a microtiter plate reader.  
Plaque reduction assay (PRA).  The antiviral activity of test compounds against influenza A virus was tested 
by PRA as previously described.3c MDCK cells were seeded at 5 x 105 cells/well into 12-well plates, and 
incubated at 37°C for 24 h. The following day, the culture medium was removed and the monolayers were 
first washed with serum-free DMEM and then infected with the flu A/PR/8/34 strain at 40 PFU/well in DMEM 
suppleŵeŶted ǁith ϭ μg/ŵL of TPCK-treated trypsin (Worthington Biochemical Corporation) and 0.14% BSA 
and incubated for 1 h at 37 °C. The influenza virus infection was performed in the presence of different 
concentrations of test compounds or solvent (DMSO) as a control. After virus adsorption, DMEM containing 
ϭ μg/ŵL of TPCK-treated trypsin, 0.14% BSA, 1.2% Avicel, and DMSO or test compounds was added to the 
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cells. At 48 h post-infection, cells were fixed with 4% formaldehyde and stained with 0.1% toluidine blue. 
Viral plaques were counted, and the mean plaque number in the DMSO-treated control was set at 100%. 
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